IP Library › Granted Patent US 12,318,361
Granted Patent B2
US 12,318,361 · App. 18/165,908 · Granted Jun 3, 2025

Methods for treating cardiovascular diseases

Inventors: Carlo Marchetti (Denver, CO); Charles A. Dinarello (Boulder, CO)
Assignee: OLATEC THERAPEUTICS, INC.
A61K31/275A61K9/0019A61K9/0053A61K9/4866A61P9/04A61P9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,361
App. No.
18/165,908
Granted
Jun 3, 2025
Kind
B2
Abstract

The present invention is directed to a method for treating cardiovascular diseases such as acute myocardial infarction, atherosclerosis, heart failure, stroke, thrombosis, carditis (including acute myocarditis, acute pericarditis and complicated pericarditis), cardiac allograft rejection, cardiomyopathy, and peripheral vascular diseases. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. A preferred route of administration is oral administration.

Claims (9)

1. A method of treating heart failure in a subject, comprising the step of:

administering to a subject suffering from heart failure an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof.

2. The method according to claim 1 , comprising administering to the subject an effective amount of dapansutrile.

3. The method according to claim 2 , wherein the subject has systolic heart failure.

4. The method according to claim 3 , wherein the subject has NYHA II-III systolic heart failure.

5. The method according to claim 2 , wherein dapansutrile is administered by systemic administration.

6. The method according to claim 5 , wherein dapansutrile is administered by oral administration.

7. The method according to claim 6 , wherein the subject is a human subject, and the dosage of dapansutrile is 1-50 mg/kg/day.

8. The method according to claim 7 , wherein the dosage of dapansutrile is 5-50 mg/kg/day.

Assignments (1)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
Continuity (5)
Division 16452189 · Jun 25, 2019
Continuation PCTUS2018012625 · Jan 5, 2018
Provisional Application 62443387 · Jan 6, 2017
Provisional Application 62506843 · May 16, 2017
Related Publication 20230277496A1 · Sep 7, 2023
References Cited (29)
US 8476316B2 · St. Laurent · 2013 [cited by applicant]
US 8829046B2 · St. Laurent · 2014 [cited by applicant]
US 8975297B2 · St. Laurent · 2015 [cited by applicant]
US 9492420B2 · St. Laurent · 2016 [cited by applicant]
US 20120157524A1 · St. Laurent · 2012 [cited by applicant]
US 20130324603A1 · St. Laurent et al. · 2013 [cited by applicant]
WO WO2012082718A2 · 2012 [cited by examiner]
Oikonomou et. al., Hellenic J. Cardiol., vol. 52, pp. 30-40, publ. 2011 (Year: 2011). [cited by examiner]
Specification Manual for Joint Commission National Quality Measure, “New York Heart Association (NYHA) Classification”, p. 1-2, publ. 2016 (Year: 2016). [cited by examiner]
“Role of immune cells in post-myocardial infarction remodeling”, Heart, 20 12, vol. 44, No. 12, p. 1480-1486, Partial English translation included. [cited by applicant]
Ajdukovic, J. “The Role of NLRP3 Inflammasome in Cardiovascular Diseases” Clinical and Experimental Cardiology; 2015; vol. 6, No. 9. 3 pages. [cited by applicant]
Skouras, Damaris, “Damaris Skouras—CEO of Olatec on Treating Inflammation”, OneMedMarket News & Information Center, Dec. 23, 2016, p. 1-4. [cited by applicant]
Toldo S. et al. “The Inflammasome in Myocardial Injury and Cardiac Remodeling” Antioxidants and Redox Signaling; 2014; 16 pages. [cited by applicant]
European Patent Office (EPO), Supplementary European Search Report cited in EP 18736230, Aug. 20, 2020. [cited by applicant]
Lee, Jie-Young , “Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection”, Experimental and Molecular Medicine, Jan. 2010, vol. 42, No. 1, pp. 6… [cited by applicant]
Marchetti, Carlo, et al., “Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse”, Journal of Cardiovascular Pharmacology, Jul. 2015, vol. 66, … [cited by applicant]
Pauschinger, Matthias , et al., “Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated i… [cited by applicant]
United States Patent & Trademark Office (USPTO), International Search Report and Written Opinion, PCT/US2018/012625, Mar. 7, 2018. [cited by applicant]
Bracey, Nathan A., et al., “The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β”, Experimental Physiology, 2013, 98.2, 2013, pp. 462-472. [cited by applicant]
Toldo S. et al. “Abstract 15506: Inhibition of the NLRP3 Inflammasome Limits the Inflammatory Injury Following Myocardial Ischemia-reperfusion in the Mouse”, The American College of Cardiology Foundation and the America… [cited by applicant]
Toldo S. et al. “Inhibition of the NLRP3 Inflammasome Limits the Inflammatory Injury Following Myocardial Ischemia-reperfusion in the Mouse”, PubMed, Apr. 2016, doi: 10.1016/j.ijacard.2016.02.043. [cited by applicant]
Supplementary European Search Report cited in EP 18736230 dated Aug. 20, 2020. 3 pages. [cited by applicant]
International Search Report for International Application No. PCT/US2018/012625. Mail Date: Mar. 7, 2018. [cited by applicant]
Lee, J-Y. et al. “Cyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection” Experimental and Molecular Medicine; Jan. 2010, vol. 42, No. 1, pp. 69… [cited by applicant]
Marchetti, C., et al., “Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse”, Journal of Cardiovascular Pharmacology, Jul. 2015, vol. 66, No.… [cited by applicant]
Pauschinger, M., et al., “Carvedilol improves left ventricular function in murine coxsackievirus- induced acute myocarditis Association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune … [cited by applicant]
Skouras, D. “Damaris Skouras—CEO of Olatec on Treating Inflammation” OneMedMarket News & Information Center; Dec. 23, 2016. 4 pages. [cited by applicant]
Toldo, S. et al. “Abstract 15506: Inhibition of the NLRP3 Inflammasome Limits the Inflammatory Injury Following Myocardial Ischemia-reperfusion in the Mouse” Circulation; Nov. 10, 2015; vol. 132; Supplement 3. 2 pages. [cited by applicant]
Toldo, S. et al. “Inhibition of the NLRP3 inflammasome limits the inflammatory injury” International Journal of Cardiology, 2016; vol. 209; pp. 215-220. [cited by applicant]